Introduction: Affecting over 25 million women across the 7 major markets, osteoporosis is a source of morbidity in the postmenopausal population. The size of the problem and its impact on healthcare budgets is expected to increase over the next decade. Osteoporosis is attracting growing R&D interest with a number of drugs in late stage development. Scope of the Report: * Evaluation of the size of the osteoporosis market based on epidemiological data and physician primary research * Assessment of the strengths and weaknesses of existing drugs classes * Analysis of drugs in late stage development *Scenario-based forecasts of penetration rates for novel parathyroid hormone therapies * Market and leading drug forecasts to 2010. Report Highlights: The release of Women's Health Initiative study data revealed increased risks of breast cancer and cardiovascular disease with long term treatment with Prempro jeopardizing sales of this brand and the class in general. Once the mainstay of osteoporosis management, HRT's use is expected to be increasingly restricted to short-term treatment of climacteric symptoms. This shift will leave a gap in the market which SERMs and bisphosphonates may be well placed to exploit. Current treatment of osteoporotic fractures involves slowing bone loss with antiresorptive agents, typically bisphosphonates. However, the launch of Forteo in 2003 will dramatically change the management of the condition. Key Reasons to Buy this Report: * Evaluates the unmet need within current osteoporosis treatment, identifying opportunities to maximize the commercial potential of pipeline therapies * Provides a breakdown of the osteoporosis population by gender and severity across the seven markets, identifying the key areas of opportunity * Provides an assessment of company portfolios and forecasts product revenues to 2010
(0 items)
